Rubrika: Zprávy

Kampaň Den vzácných onemocnění 2023

Join our campaign for Rare Disease Day! February 28th is Rare Disease Day, where the rare community comes together, finds support and raises awareness for rare diseases across the globe […]

Aktuální informace společnosti Roche/Genentech o studii GENERATION HD2

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Společnost Novartis ukončuje studii VIBRANT-HD

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

Mezinárodní huntingtonská asociace obdržela velmi štědrý dar

International Huntington Association has received a very generous donation. A Norwegian donor is behind the donation. He wishes to remain anonymous. The money is earmarked for a new position at […]

Společnost uniQure oznámila, že obnovuje nábor pacientů do studie AMT-130 ve vyšších dávkách.

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Společnost Wave Life Sciences oznamuje pozitivní výsledky studie fáze 1b/2a SELECT-HD s prvními výsledky naznačujícími selektivní zapojení alel do cílové skupiny pomocí WVE-003 u Huntingtonovy choroby

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

Společnost uniQure oznamuje aktualizované informace o kohortě s nízkými dávkami v klinické studii fáze I/II genové terapie AMT-130 pro léčbu Huntingtonovy choroby

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Společnost Annexon Biosciences aktualizuje výsledky studie

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Květen - měsíc informovanosti

May Awareness Month 2022 came to an end. Between the webinars, weekends away and Light It Up For HD, there were a lot of initiatives coming from all the different […]

Webinář - Prozkoumat pro Huntington: Dobrodružství Dimitriho Poffé v Latinské Americe

To finish May Awareness Month in the most inspiring and hopeful way possible, the International Huntington Association and European Huntington Association had a webinar with Dimitri Poffé, a Huntington’s Disease […]